A Phase 1 interventional study of ACM-CpG immunotherapy in patients with inoperable peritoneal metastases or malignant ascites
Recruiting Phase 1 NCT07658196
Study Description
A clinical trial testing the safety and best dose of a new immunotherapy treatment (ACM-CpG) delivered directly into the abdomen for patients whose cancer has spread to the lining of the belly or who have fluid build-up caused by cancer
Study Details
- Registry ID:
- NCT07658196
- Conditions:
- Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
- Phase:
- Phase 1
- Target Enrollment:
- 24 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Rhode Island and the Miriam Hospitals (Brown University Health)
Providence, Rhode Island, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.